Literature DB >> 9548661

Japan Pancreatic Cancer Registry: current status.

M Yamamoto1, O Ohashi, Y Saitoh.   

Abstract

The Pancreatic Cancer Registration Committee of the Japan Pancreas Society registered a total 17,130 patients with pancreatic cancer from 350 major hospitals in Japan from 1981 through 1995. Diagnosis with ultrasonography and computed tomography has become increasingly important as the methods used for first detecting a pancreatic lesion. Tumor resection was performed in 36% of the patients, and the 5-year survival rate of the patients who received resection was 18.2%. The rate of resection and results of surgical treatment have improved, which may be attributed to the increase in detection of resectable tumor and benefits of aggressive and extended surgery.

Entities:  

Mesh:

Year:  1998        PMID: 9548661     DOI: 10.1097/00006676-199804000-00006

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  18 in total

Review 1.  Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.

Authors:  Domenico Tamburrino; Deniece Riviere; Mohammad Yaghoobi; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2016-09-15

2.  Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer.

Authors:  Jun Yu; Kenoki Ohuchida; Kazuhiro Mizumoto; Nami Ishikawa; Yasuhiro Ogura; Daisuke Yamada; Takuya Egami; Hayato Fujita; Seiji Ohashi; Eishi Nagai; Masao Tanaka
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

3.  Genetic progression and divergence in pancreatic carcinoma.

Authors:  M Yamano; H Fujii; T Takagaki; N Kadowaki; H Watanabe; T Shirai
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

4.  Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer.

Authors:  Ryuichiro Doi; Kazuhiro Kami; Daisuke Ito; Koji Fujimoto; Yoshiya Kawaguchi; Michihiko Wada; Masafumi Kogire; Ryo Hosotani; Masayuki Imamura; Shinji Uemoto
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

Review 5.  Cancer registries in Japan: National Clinical Database and site-specific cancer registries.

Authors:  Takayuki Anazawa; Hiroaki Miyata; Mitsukazu Gotoh
Journal:  Int J Clin Oncol       Date:  2014-11-08       Impact factor: 3.402

6.  Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial.

Authors:  Ryuichiro Doi; Masayuki Imamura; Ryo Hosotani; Toshihide Imaizumi; Takashi Hatori; Ken Takasaki; Akihiro Funakoshi; Hideyuki Wakasugi; Takehide Asano; Shoichi Hishinuma; Yoshiro Ogata; Makoto Sunamura; Koji Yamaguchi; Masao Tanaka; Sonshin Takao; Takashi Aikou; Koichi Hirata; Hiroyuki Maguchi; Koichi Aiura; Tatsuya Aoki; Akira Kakita; Makoto Sasaki; Masahiko Ozaki; Satoru Matsusue; Shunichi Higashide; Hideki Noda; Seiyo Ikeda; Shunzo Maetani; Shigeaki Yoshida
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

7.  MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation.

Authors:  Jun Yu; Kenoki Ohuchida; Kazuhiro Mizumoto; Norihiro Sato; Tadashi Kayashima; Hayato Fujita; Kouhei Nakata; Masao Tanaka
Journal:  Mol Cancer       Date:  2010-06-28       Impact factor: 27.401

8.  Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosis.

Authors:  Yuki Hattori; Toshifumi Gabata; Osamu Matsui; Kentaro Mochizuki; Hirohisa Kitagawa; Masato Kayahara; Tetsuo Ohta; Yasuni Nakanuma
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

9.  Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.

Authors:  Chang F Qu; Emma Y Song; Yong Li; Syed M A Rizvi; Chand Raja; Ross Smith; Alfred Morgenstern; C Apostolidis; Barry J Allen
Journal:  Clin Exp Metastasis       Date:  2006-02-11       Impact factor: 5.150

10.  LIM only 4 is overexpressed in late stage pancreas cancer.

Authors:  Jun Yu; Kenoki Ohuchida; Kohei Nakata; Kazuhiro Mizumoto; Lin Cui; Hayato Fujita; Hiroshi Yamaguchi; Takuya Egami; Hidehisa Kitada; Masao Tanaka
Journal:  Mol Cancer       Date:  2008-12-22       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.